Citations

Showing 10 of 108081 citations.

Kita, Hirohito

Mayo Clinic

Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology | March 18, 2017 | Volume: 14 | Issue: 3 | Pages: 303-303

10.3388/jspaci.14.303 Get It

Acute Changes in Left Atrial Pressure After MitraClip Are Associated With Improvement in 6-Minute Walk Distance
Maor, Elad , Panaich, Sidakpal , Reeder, Guy S., Nishimura, Rick A., Rihal, Charanjit S. , Eleid, Mackram F. , Raphael, Claire E. , Panaich, Sidakpal S, Nkomo, Vuyisile T. , Rihal, Charanjit S. , Panaich, Sidakpal S , Maor, Elad

Mayo Clinic

Circulation: Cardiovascular Interventions | March 18, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circinterventions.116.004856 | PMID 28314742 Get It

Background— Data on the clinical use of left atrial (LA) hemodynamic monitoring during MitraClip procedure are limited. This study evaluated the association between intraprocedural changes in LA pressure after MitraClip and improvement in exercise capacity as documented by 6-minute walk test (6MWT). Methods and Results— Study population included 50 patients who underwent MitraClip at the Mayo Clinic (Rochester, MN), between June 2014 and July 2016 and completed both baseline and 30-day follow-up 6MWT. Primary outcome for the current analysis was defined as 6MWT improvement above the median. Mean age of the study population was 79±10 years, and 34 (68%) were men. Baseline preprocedural 6MWT distance was 308 m (interquartile range [IQR], 234–394 m). Acute, intraprocedural change in LA pressure after MitraClip was 3 mm Hg (IQR, 1–6 mm Hg), and change in V wave was 11 mm Hg (IQR, 6–19 mm Hg). Median 6MWT improvement was 25 m (IQR, 19–47 m). Univariate analysis showed that patients with ≤ mild postprocedural mitral regurgitation were 4-fold more likely to experience an improvement in 6MWT ( P =0.02). Multivariate model demonstrated that each 5 mm Hg decrease in V wave was associated with 49% increased likelihood for improvement in 6-minute walk ( P =0.04). Similar model with V-wave change as a dichotomous variable showed that patients with a V-wave decrease of ≥11 mm Hg were 3.8× more likely to improve their 6MWT ( P =0.05). Conclusions— Acute changes in LA pressure after MitraClip procedure are associated with clinical improvement as measured by 6MWT. Continuous LA pressure monitoring may be a useful tool for procedural guidance during transcatheter mitral repair.
Contemporary carotid imaging: from degree of stenosis to plaque vulnerability
Brinjikji, Waleed , Kim, Gyeong‐Moon , Huston, John , Rabinstein, Alejandro A. , Lerman, Amir , Lanzino, Giuseppe

Mayo Clinic

Journal of Neurosurgery | March 17, 2017 | Volume: 2016 | Issue: 1 | Pages: 27-42

10.3171/2015.1.jns142452.test Get It

Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis
Tandon, Nidhi , Sidana, Surbhi , Lacy, Martha Q. , Dingli, David , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Kumar, Shaji , Buadi, Francis K. , Fonder, Amie L, Hwa, Yi Lisa, Leung, Nelson , Go, Ronald S , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent , Russell, Stephen J , Sidana, Surbhi , Dingli, David

Mayo Clinic

American Journal of Hematology | March 17, 2017 | Volume: 92 | Issue: 6 | Pages: 549-554

10.1002/ajh.24723 | PMID 28314084 Get It

AbstractWe analyzed the outcomes following initial relapse or refractory disease in systemic light chain amyloidosis (AL) and the impact of type of therapy employed.A total of 1327 patients with AL seen at Mayo Clinic within 90 days of diagnosis, between 2006 and 2015, were reviewed. The study included 366 patients experiencing a documented hematological or organ relapse or refractory disease requiring start of second line therapy. Overall survival (OS) and time to next treatment (TTNT) were calculated from start of second line treatment.The median time to require second line treatment was 16.2 months (1‐93) from the start of first line therapy. At relapse, patients received proteasome inhibitors (PI; 45.1%), immunomodulators (IMiD; 22.7%), alkylators (9%), PI and IMiD combination (4.1%), autologous transplant (3.8%), steroids and other therapies (4.9%). Among these, 124 (33.9%) required change or reinstitution of therapy. The median time to require third line treatment was 31 months (95% CI; 24, 40.5) and the median overall survival (OS) was 38.8 months (95% CI; 29.6, 52.6) from the start of second line treatment. Retreatment with same therapy at relapse significantly reduced TTNT (22 m vs 32.3 m; P = .01) as compared to different therapy; but did not have any impact OS (30.8 m vs 51.1 m; P = .5). In conclusion, this study provides important information about outcomes of patients with AL who require second line treatment for relapsed/refractory disease . Treatment with a different therapy at relapse improves time to next therapy but does not impact OS.
Epidemiology, risk factors, and outcome of Clostridium difficile infection in heart and heart‐lung transplant recipients
Bruminhent, Jackrapong , Petterson, Tanya M. , Kremers, Walter K. , Cawcutt, Kelly A., Cawcutt, Kelly , Thongprayoon, Charat , Razonable, Raymund R. , Bruminhent, Jackrapong , Kremers, Walter K

Mayo Clinic

Clinical Transplantation | March 17, 2017 | Volume: 31 | Issue: 6 | Pages: No page available

10.1111/ctr.12968 | PMID 28314071 Get It

Abstract Background Clostridium difficile is a major cause of diarrhea in thoracic organ transplant recipients. We investigated the epidemiology, risk factors, and outcome of Clostridium difficile infection ( CDI ) in heart and heart‐lung transplant ( HT ) recipients. Methods This is a retrospective study from 2004 to 2013. CDI was defined by diarrhea and a positive toxigenic C. difficile in stool measured by toxin enzyme immunoassay (2004‐2006) or polymerase chain reaction (2007‐2013). Cox proportional hazards regression was used to model the association of risk factors with time to CDI and survival with CDI following transplantation. Results There were 254 HT recipients, with a median age of 53 years ( IQR , 45‐60); 34% were female. During the median follow‐up of 3.1 years ( IQR , 1.3‐6.1), 22 (8.7%) patients developed CDI . In multivariable analysis, risk factors for CDI were combined heart‐lung transplant ( HR 4.70; 95% CI , 1.30‐17.01 [ P =.02]) and retransplantation ( HR 7.19; 95% CI , 1.61‐32.12 [ P =.01]). Acute cellular rejection was associated with a lower risk of CDI ( HR 0.34; 95% CI , 0.11‐0.94 [ P =.04]). CDI was found to be an independent risk factor for mortality ( HR 7.66; 95% CI , 3.41‐17.21 [ P <.0001]). Conclusions Clostridium difficile infection after HT is more common among patients with combined heart‐lung and those undergoing retransplantation. CDI was associated with a higher risk of mortality in HT recipients.
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
Patnaik, Mrinal M. , Barraco, Daniela , Finke, Christy M. , Reichard, Kaaren K. , Hoversten, Katherine P., Ketterling, Rhett P. , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | March 17, 2017 | Volume: 92 | Issue: 6 | Pages: 542-548

10.1002/ajh.24722 | PMID 28314085 Get It

AbstractAtypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly‐annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8%, and PTPN11 4%. Fifteen patients (60%) had >1 mutation, while 9 (36%) had ≥3. The median overall survival (OS) was 10.8 months and at last follow up (median 11 months), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. On univariate analysis, survival was adversely impacted by advanced age (P = .02), low hemoglobin (P = .01), red blood cell transfusion dependence (P = .03), high white blood cell count (P = .02), TET2 (P = .03), NRAS (P = .04), PTPN11 (P = .02) mutations and the presence of ≥3 gene mutations (P = .006); ASXL1, SETBP1, and ETNK1 mutations did not impact OS. In multivariable analysis, advanced age (P = .003) [age >67: HR 10.1, 95% CI 1.3‐119], low hemoglobin (P = .008) [HB< 10 gm/dL: HR 8.2, 95% CI 1.6‐23.2] and TET2 mutations (P = .01) [HR 8.8, 95% CI 1.6‐47.7] retained prognostic significance. We then used age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations (each counted as one risk factor) to create a hazard ratio weighted prognostic model; effectively stratifying patients into two risk categories, low (0‐1 risk factor) and high (≥2 risk factors), with median OS of 18 and 7 months, respectively.
Impact of atrial fibrillation on platelet gene expression
Wysokiński, Waldemar E. , Tafur, Alfonso , Ammash, Naser M., Asirvatham, Samuel J. , Wu, Yanhong , Gosk−Bierska, Izabela , Grill, Diane E. , Slusser, Joshua P. , Mruk, Jozef S., McBane, Robert D. , Ammash, Naser, Wysokinski, Waldemar , McBane, Robert , Asirvatham, Samuel J

Mayo Clinic

European Journal of Haematology | March 17, 2017 | Volume: 98 | Issue: 6 | Pages: 615-621

10.1111/ejh.12879 | PMID 28306170 Get It

AbstractAimsPlatelets retain cytoplasmic messenger RNA and are capable of protein biosynthesis. Several diseases are known to impact the platelet transcriptome but the effect of non‐valvular atrial fibrillation (NVAF) on platelet RNA transcript is essentially unknown. The aim of this study was to evaluate the impact of NVAF on platelet RNA transcript by measuring platelet genes expression in consecutive NVAF patients before and 3‐4 months after pulmonary vein isolation (PVI) and compared to normal sinus rhythm controls (NSR).Methods and ResultsRNA from isolated platelets were reverse transcribed, assayed against 15 genes using real‐time qPCR, and expressed as mean cycle threshold (ΔCt) using beta‐2‐microglobulin as endogenous control. Expression of all evaluated genes, except cathepsin A gene, was significantly lower (higher ΔCt) in 103 NVAF patients compared to 55 NSR controls. Insulin‐like growth factor binding protein acid labile subunit gene (IGFALS) had expression more than 16 fold‐lower (17.0±2.8 vs 12.5±3.8, P<.001), follow by genes encoding for prostacyclin receptor, and for von Willebrand factor which had fourfold lower expression compared to NSR controls. Gender, type of atrial fibrillation, heart failure, hypertension, prior stroke, diabetes mellitus, and atherosclerosis were associated with different gene expression. Following PVI, expression of four genes significantly increased, particularly IGFALS gene (increased 256‐fold) and ADAMT gene increased 16‐fold); expression of three genes significantly decreased, and expression of eight genes has not changed.ConclusionsPlatelets are capable to respond to the circulatory environment of NVAF by altering transcript and changing prothrombotic status. This shows platelet potential for molecular “reprogramming” possibly induced by flow disturbances of NVAF.
Screening for Burnout in Emergency Medicine Residents: Now What?
Goyal, Deepi G. , Dyrbye, Liselotte N. , Shanafelt, Tait D.

Mayo Clinic

AEM Education and Training | March 17, 2017 | Volume: 1 | Issue: 2 | Pages: 79-80

10.1002/aet2.10036 | PMID 30051014 Get It

Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)
Pignolo, Robert J. , Mukaddam, Mona Al , Shore, Eileen M. , Kaplan, Frederick S.

Mayo Clinic

Expert Opinion on Orphan Drugs | March 17, 2017 | Volume: 5 | Issue: 4 | Pages: 291-294

10.1080/21678707.2017.1304211 | PMID 29177121 Get It

Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review
Weymann, Alexander , Sabashnikov, Anton , Popov, Aron-Frederik, Mirhosseini, Seyed Jalil , Nombela‐Franco, Luis , Testa, Luca , Lotfaliani, Mohammadreza , Zeriouh, Mohamed, Liu, Tong , Dehghan, Hamidreza , Yavuz, Şenol , Sá, Michel Pompeu , Gong, Mengqi, Benedetto, Umberto , Dohmen, Pascal M., Deshmukh, Abhishek , Calkins, Hugh , Stone, Gregg W. , [IMCSC-Group], Integrated Meta-Analysis of Cardiac Surgery and Cardiology-Group, Ali‐Hasan‐Al‐Saegh, Sadeq , Baker, William L. , Jang, Jae‐Sik , D’Ascenzo, Fabrizio , Biondi‐Zoccai, Giuseppe , [IMCSC-Group], Integrated Meta-Analysis of Cardiac Surgery and Cardiology-Group, Nombela-Franco, Luis , Sá, Michel Pompeu

Mayo Clinic

Medical Science Monitor Basic Research | March 17, 2017 | Volume: 23 | Issue: No issue available | Pages: 58-86

10.12659/msmbr.902557 | PMID 28302997 Get It